June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Baseline Predictors of improvement in self-reported visual function following treatment with ranibizumab in patients with diabetic macular edema
Author Affiliations & Notes
  • Rohit Varma
    Ophthalmology and Visual Sciences, University of Illinois at Chicago Eye and Ear Infirmary, Chicago, IL
  • Neil Bressler
    Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Chantal Dolan
    Genentech, Inc., South San Francisco, CA
  • Linda Yau
    Genentech, Inc., South San Francisco, CA
  • James Ward
    Genentech, Inc., South San Francisco, CA
  • Shoshana Colman
    Genentech, Inc., South San Francisco, CA
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rohit Varma, Neil Bressler, Chantal Dolan, Linda Yau, James Ward, Shoshana Colman; Baseline Predictors of improvement in self-reported visual function following treatment with ranibizumab in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4026.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To identify predictors of improvement in patient-reported visual function following 24 months of every 4 week treatment with ranibizumab in patients with diabetic macular edema (DME) enrolled in the RIDE and RISE clinical trials.

Methods: Data from RIDE and RISE were pooled to identify predictors of overall composite score improvement from baseline to 24 months in patient-reported visual function measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Predictors were chosen from a set of 28 candidate variables considered to be potentially important predictors by the authors using two approaches: 1) a multivariate stepwise selection procedure from the full set of 28 candidate variables (P<0.05 criterion for inclusion) and 2) a univariate selection procedure identifying variables one at a time (P<0.10 criterion for inclusion) to be included in a final multivariate model utilizing stepwise selection procedure (p<0.05 criterion for inclusion). Parameter estimates and associated P-values for a combined screening model derived from (1) and (2) were obtained using the SAS GLM procedure.

Results: There were 605 study participants with NEI VFQ-25 scores at both baseline and month 24. Predictors of improvement in patient-reported vision function in the combined screening model included the following: treatment with ranibizumab vs sham (P = 0.03), higher baseline contrast sensitivity in the untreated eye (P<0.001), lower baseline systolic blood pressure (P<0.03) and lower baseline NEI-VFQ-25 composite score (P<0.0001).

Conclusions: These data suggest that treatment with ranibizumab and lower self-reported visual function at baseline are associated with improved patient-reported visual function. No features have been identified which would preclude ranibizumab treatment for DME based on patient-reported visual function outcomes. Of particular note, baseline visual acuity in the treated eye does not necessarily predict improvement in self-reported visual function.

Keywords: 754 visual acuity • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×